ACXP — Acurx Pharmaceuticals, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1736243 ·
Last close
$0.99
Market Cap
$6.00M
52W High
$7.54
52W Low
$0.90
ADV30
101,096
Next earnings
2026-11-12
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 0 | — | -2,307,228 | -2,254,173 | 10,984,777 | 10,656,386 | 2,832,746 |
| Mar 2026 | 0 | — | -1,715,990 | -1,680,982 | 9,539,952 | 9,254,813 | 2,526,809 |
| Dec 2025 | 0 | — | -1,617,116 | -1,578,276 | 7,689,535 | 7,556,100 | 2,420,943 |
| Sep 2025 | 0 | — | -2,028,701 | -1,992,790 | 6,105,211 | 5,906,802 | 2,468,175 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-6,183,194
Investing CF
—
Financing CF
$10,775,452
CapEx
—
Dividends Paid
—
Buybacks
$0
EPS Diluted TTM
$-4.27
As of
2026-11-15
Balance + Analyst (yfinance extras)
Retained Earnings
$-79,223,649
Inventory
—
Receivables
$95,307
ST Investments
—
EBIT TTM
$-7,669,035
Pretax Income TTM
$-7,506,221
Interest Exp TTM
—
Analysts
3
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -8,091,983 | -7,966,538 | 7,689,535 | 2,420,943 | 5,268,592 | -6,787,782 |
| Dec 2024 | 0 | -14,123,227 | -14,103,103 | 3,857,963 | 3,242,842 | 615,121 | -10,383,431 |
| Dec 2023 | 0 | -14,577,768 | -14,577,768 | 7,709,123 | 3,042,438 | 4,666,685 | -9,800,885 |
| Dec 2022 | 0 | -12,092,776 | -12,092,776 | 9,376,706 | 2,061,685 | 7,315,021 | -7,542,290 |
TTM Snapshot
Revenues TTM
$190,104
NetIncome TTM
$-7,506,221
OpCashFlow TTM
—
Assets (Latest)
$10,984,777
Forward EPS
$-1.78
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| FBLG | FibroBiologics, Inc. | $6.00M | $0.90 | — |
| CNSP | CNS Pharmaceuticals, Inc. | $6.07M | $4.15 | — |
| SNGX | SOLIGENIX, INC. | $6.11M | $0.28 | — |
| INNPF | INNOCAN PHARMA Corp | $5.80M | $1.29 | — |
| GTBP | GT Biopharma, Inc. | $5.74M | $3.18 | — |
News headlines (Yahoo Finance, 1h cache)
Acurx Pharmaceuticals, Inc. Q3 2026 Earnings Call Summary
2026-11-12 18:00 · Yahoo
Acurx Pharmaceuticals, Inc. Reports Third Quarter 2026 results and provides business update
2026-11-12 12:01 · Yahoo
Acurx Pharmaceuticals to Discuss Third Quarter 2026 Financial Results on November 12, 2026 Conference Call and Provide Business Update
2026-10-26 12:01 · Yahoo
Acurx Announces Publication in ASM Confirming Data on its DNA pol IIIC Inhibitor Pipeline of Antibiotics Demonstrating a Potential Microbiome-Sparing Class Effect
2026-10-21 12:01 · Yahoo
Acurx Pharmaceuticals Takes Its Antibiotics Story Global Through a 12-Month Series with New to The Street
2026-10-05 17:25 · Yahoo
Acurx Pharmaceuticals Announces First Patient Enrolled in PATHFINDER Clinical Trial of Ibezapolstat in Multiply-Recurrent C. difficile Infection
2026-09-29 12:01 · Yahoo
New to The Street Broadcasts Tonight at 6:30 PM ET Across the United States, Latin America and MENA, Featuring BioVie, Acurx Pharmaceuticals, Lantern Pharma and SafeSpace Global
2026-09-19 15:45 · Yahoo
Acurx Announces Presentation of a Scientific Poster at the Premier International C. difficile Symposium (ICDS) Demonstrating Superior In Vitro Kill Kinetics of Ibezapolstat vs. Vancomycin and Fidaxomi
2026-09-14 12:01 · Yahoo
Acurx Pharmaceuticals Inc (ACXP) (Q2 2026) Earnings Call Highlights: FDA Signals Potential ...
2026-08-21 01:02 · Yahoo
Acurx Pharmaceuticals, Inc. Reports Second Quarter 2026 results and provides business update
2026-08-14 11:01 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.